Meeting
2014 ASCO Annual Meeting
Prevention of irinotecan-induced diarrhea by probiotics: Randomized double-blind, placebo-controlled phase III study.
Authors
Michal Mego
Faculty of Medicine, Comenius University and National Cancer Institute, Bratislava, Slovakia
Michal Mego , Jozef Chovanec , Iveta Andrezalova , Peter Konkolovsky , Milada Mikulova , Maria Reckova , Vera Miskovska , Branislav Bystricky , Lenka Medvecova , Dagmar Mikusova , Adela Lagin , Daniela Svetlovska , Stanislav Spanik , Jozef Mardiak , Vladimir Zajac , Lubos Drgona
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Palliative Care and Symptom Management
Clinical Trial Registration Number
NCT01410955
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 9611)
DOI
10.1200/jco.2014.32.15_suppl.9611
Abstract #
9611
Poster Bd #
261
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Elsiglutide in the primary prevention of chemotherapy (CT)-induced diarrhea in patients with colorectal cancer (CRC) receiving 5-fluorouracil (5-FU)-based CT: A multinational, randomized, double-blind, placebo-controlled study.
First Author: Meinolf Karthaus
Poster
2015 ASCO Annual Meeting
LUME-Colon 1: A double-blind, randomized phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer (CRC) refractory to standard therapies.
First Author: Heinz-Josef Lenz
Poster
2015 ASCO Annual Meeting
Placebo-controlled, double-blinded multi-center phase III trial of XELIRI/FOLFIRI plus simvastatin in metastatic colorectal cancer.
First Author: Sung Hee Lim
Poster
2013 ASCO Annual Meeting
Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC).
First Author: Tamas Pinter